AdAlta Limited is a drug discovery and development company focused on using its powerful technology platform to generate a promising new class of protein therapeutics, known as i-bodies, for treating a wide range of human diseases.
i-bodies are a human analogue of the antigen binding domain of the shark antibody; they combine the high target specificity and affinity advantages of antibodies with the beneficial features of small molecule drugs.
The Company’s lead i-body candidate, AD-114, is being developed for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases, for which current therapies are sub-optimal and there is a high-unmet medical need. AdAlta intends to continue further discovery and development activities directed towards other disease targets for in-house development or partnering.
Both AdAlta’s i-body technology platform and lead i-body drug candidate, AD-114, are protected by a strong portfolio of worldwide granted patents and pending applications.
AdAlta is headquartered in Melbourne, Australia.